Biodexa (BDRX) news
Recent news
Biodexa Pharmaceuticals - files for resale of 2.56 mln ADSs by selling shareholders - SEC filing
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has filed with the U.S. Securities and Exchange Commission (SEC) to register the resale of 2,560,000 American Depositary Shares (ADSs) by selling shareholders, according to a recent SEC filing . The registration is part of the company’s ongoing efforts to…
AInvest Wire · Jul 15, 2026Biodexa Pharmaceuticals - receives Health Canada approval to expand Phase 3 FAP trial into Canada
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has announced that it has received regulatory approval from Health Canada to expand its Phase 3 Serenta clinical trial for eRapa into Canada. This development follows the successful activation of the first European site at the University of Bonn in…
AInvest Wire · Jun 29, 2026Landfar Bio Medicine says share trade to halt on June 11 to remove delisting risk warning, trading to resume June 12
Landfar Bio Medicine has announced that trading of its shares will be temporarily suspended on June 11, 2026, to address a delisting risk warning from the Nasdaq Stock Market. The company plans to delist its securities voluntarily to avoid potential regulatory action and will seek to relist on a…
AInvest Wire · Jun 10, 2026ImportantBiodexa stock rallies amid release of Phase 2 data for eRapa
Biodexa stock rallies amid release of Phase 2 data for eRapa Biodexa (BDRX), a clinical-stage biopharmaceutical company specializing in innovative treatments for diseases with unmet medical needs, experienced a significant surge in its stock price on Tuesday, following the release of encouraging…
AInvest Wire · Jul 11, 2024ImportantBiodexa Pharma Shares Double After Licensing Deal for Tolimidone
AInvest Wire · Nov 27, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.